SUMO-specific protease 1 (SENP1) is a member of de-SUMOylation protease family and has an important role in the regulation of androgen receptor-dependent transcription and hypoxia signaling. This activity profile of SENP1 prompted us to investigate whether SENP1 is involved in the pathogenesis of prostate cancer. In previous studies, we have detected the overexpression of SENP1 in both precancerous prostate intraepithelial neoplasia (PIN) lesions and prostate cancer tissue samples from patients. Whereas our whole-animal model has demonstrated that SENP1 induction is critical for prostate cell transformation, the role of SENP1 in prostate cancer progression is still unknown. In this study, we show that SENP1 expression directly correlates with prostate cancer aggressiveness and reccurrence, by analyzing more than 150 prostate cancer specimens. Modulating SENP1 level dictates colony formation of prostate cancer cell lines, tumor growth in nude mice and also prostate cancer cell migration and invasion. Silencing SENP1 level in highly metastatic prostate cancer cells perturbs their ability to metastasize to the bone and initiates secondary tumors. Mechanistically, the expression of two critical bone remodeling proteins, matrix metalloproteinase 2 (MMP2) and MMP9, is regulated by SENP1 through the HIF1a signaling pathway. All these results show the contribution of SENP1 to the progression of prostate cancer, and suggest that SENP1 may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients.
INTRODUCTION
SUMO modification of protein is a dynamic process that modulates the target protein's activation, function and/or subcellular localization. 1 SUMOylation is catalyzed by SUMOspecific activating (E1), conjugating (E2) and ligating (E3) enzymes, and is reversed by a family of Sentrin/SUMO-specific proteases (SENPs). 2 These enzymes have a critical role in maintaining a balance between the level of SUMOylated and unmodified proteins that mediated SUMOylation-dependent cellular physiology. 1 In most cases, deconjugation mediated by SENPs is an inducible process. Accumulated evidences show that SENPs are dominant factors in the regulation of the physiological and pathological process mediated by SUMOylated proteins.
1 SENP1, a member of the SENP family, has been reported to target androgen receptor, HDAC1, Sirt1, HIF1a, Gata1, reptin, Elk1 and HIPK1 for de-SUMOylation. [3] [4] [5] [6] [7] [8] Studies in SENP1-knockout mice define a role of SENP in placental development and erythropoiesis. 7, 9 In previous publications, we have shown that SENP1 markedly enhances androgen receptor-dependent transcription through de-SUMOylation of HDAC1. 6 In an interesting feedback mechanism, the androgen receptor directly initiates SENP1 gene transcription to maintain elevated SENP1 levels in prostate cancer cells. 10 This overexpression of SENP1 is detected in both prostate cancer tissue and precancerous prostate intraepithelial neoplasia (PIN) lesions. 11 We have subsequently demonstrated that the induction of SENP1 is necessary for prostate cell transformation, as an androgen-driven murine SENP1 overexpressed in the prostate gland caused hyperplasia that progressed to high-grade PIN. 12 In addition, we have also observed that the onset of PIN in these SENP1-transgenic mice was accompanied by induction of HIF1a, VEGF and angiogenesis. Angiogenesis is the primary step in the formation of metastatic disease, but it remains to be determined whether SENP1 contributes to metastasis of prostate cancer cells.
Therefore, in our present study, we have analyzed more than 150 human prostate cancer specimens to determine whether SENP1 expression is correlated to metastatic prostate cancer. We also used in vitro and in vivo assays performed in prostate cancer cell lines to demonstrate that SENP1 is an essential mediator of prostate cancer progression and metastasis to the bone.
RESULT AND DISCUSSION
In our previous study, we found enhanced SENP1 mRNA levels in PIN and prostate cancer as compared with adjacent normal prostate epithelia by in situ hybridization. 11 However, it is unknown whether the expression of SENP1 correlates with the aggressiveness of the disease. Therefore, we analyzed a large number of prostate cancer specimens from prostatectomy patients to test the relationship between the SENP1 induction and the Gleason score. As shown in Figure 1a , patient samples with higher SENP1 scores corresponded with higher Gleason scores, suggesting that the expression of SENP1 is associated with more aggressive disease. To further validate this correlation, we tested whether the expression of SENP1 is related to prostate cancer recurrence. Prostate cancer patients with high SENP1 levels were more prone to prostate cancer recurrence than patients who exhibited low SENP1 levels (Figure 1b) . Collectively, the data demonstrate that the expression of SENP1 is correlated with the severity of prostate carcinoma.
To further determine the role of SENP1 in prostate cancer, we analyzed the tumorigenesis of prostate cancer cell lines after the alteration of SENP1 expression in these cells. As shown in Figure 2a , the colony formation of LNCaP cells stable-transfected with SENP1 (Supplementary Figure S1a) was greatly increased in comparison with that of Vector-LNCaP cells. SENP1-silenced in PC3 cells (si-SENP1-PC3) (Supplementary Figure S1b) , a prostate cancer cell line with relatively high SENP1 expression and highly metastatic potentials, significantly decreased its colony formation abilities (Figure 2b ). In addition, we also injected si-SENP1-or si-NS-PC3 cells subcutaneously into both flanks of male nude mice, and found that tumor growth was significantly attenuated in si-SENP1-PC3 (Figure 2c) .
The above results suggest that the elevated expression of SENP1 in prostate cancer cells might contribute to both tumor growth and aggressiveness. To further evaluate the role of SENP1 in prostate cancer metastasis, we examined the invasion and migration ability of SENP1-overexpressing LNCaP-and SENP1-knockdown PC3 cells independently. The overexpression of SENP1 increased the invasion of LNCaP cells through Matrigel-coated filters by threefold to fourfold (Figure 3a) . Consistently, silencing SENP1 expression in PC3 cells (si-SENP1-PC3) significantly decreased the invasion ability ( Figure 3a) . We further assessed the LNCaP cell migration ability by physically wounding cells plated on the cell culture dishes. As shown in Figure 3b , at 24 h after being scrubbed, SENP1-LNCaP cells were able to migrate faster than Vector-LNCaP cells. Conversely, the migration ability of si-SENP-PC3 cells was significantly decreased in comparison with that of si-NS-PC3 cells in the Boyden chamber assay (Figure 3c ). These results from in vitro assays strongly suggest that SENP1 regulates the migratory and invasive properties of prostate cancer cells.
The vast majority of prostate cancer-related deaths results from the metastasis to the bone. However, the mechanism that prostate cancer cells use to initiate secondary tumor formation in the bone is relatively undefined. Hence, we generated a mouse model of bone metastasis to determine the role of SENP1 in bone metastasis of prostate cancer cells; specifically, intracardiac injection of PC3 cells led to metastasis of these cells selectively to bone. The si-SENP1-PC3 or si-NS-PC3 cells (5 Â 10 6 of each) were injected into male athymic mice via the left ventricle in 100 ml PBS. At 35 days after injection, mice were anesthetized, and the metastatic lesions in bone were radiographed using a Faxitron MX-20 machine (Tucson, AZ, USA). As shown in Figure 3d , 11 lesions from 8 of 10 mice injected with si-NS-PC3 cells had detectable metastasis lesions, mostly in the distal femurs and proximal tibias, whereas only four lesions from 4 of 10 of the mice injected with si-SENP1-PC3 exhibited such metastatic lesions. These metastasis lesions were confirmed by staining a section with hematoxylin and eosin (Figure 3d ). These data reveal that SENP1 contributes to the formation of secondary tumors in the bone and hence is important in metastatic prostate cancer.
We have previously showed that SENP1 can specifically stabilize HIF1a through de-SUMOylation and regulate its transcriptional activity during hypoxia. 7 Accumulated documents show that HIF1a has an important role in tumor progression. 13 A limited set of HIF1a-target genes has been identified to process the tumor progression and invasion. These genes include matrix metalloproteinases (MMPs), vimentin and fibronectin. 13 MMPs are a family of enzymes that cleave a broad range of components of extracellular matrix, basement membrane, growth factors and cell surface receptors. The MMPs are critical contributors to the increase in bone remodeling and invasive properties of metastatic prostate cancer cells. 14, 15 Hence, it is not surprising that several MMPs are overexpressed in prostate cancer progression. 16 In fact, increased expression of MMP2 in cancer cells has been shown as a predictor of decreased prostate cancer disease-free survival. [17] [18] [19] [20] MMPs are currently being evaluated for their Figure S4) . The score was given ranging from 0 to 3 based on the percent area stained and immunostaining intensity on TMA. The data are presented as means ± s.e.m. (b) Kaplan-Meier curves showing failure-free survival of 117 prostate cancer patients following radical prostatectomy as a function of SENP1 expression in cancer tissues determined by immunohistochemistry (log-rank test, P ¼ 0.0252). A retrospective analysis for the outcome assessment was based on the detailed anonymized clinico-pathological information linked to the TMA technique specimens. Failure-free was defined as a PSA elevation o0.2 ng ml À 1 after radical prostatectomy level.
SENP1 regulates prostate cancer progression Q Wang et al prognostic value. As SENP1 expression appears to be critical for prostate cancer invasion and bone metastasis, we reasoned that SENP1 might regulate MMP expression in the prostate cancer. To assess whether SENP1 regulates MMP expression in prostate cancer cells, the expression of several MMP family members in si-SENP1-or si-NS-PC3 cells was measured by real-time PCR and western blot analysis. The expression levels of MMP2 and MMP9 were markedly decreased in si-SENP1-PC3 cells in comparison with that in si-NS-PC3 cells (Figure 4a and Supplementary Figure S3 ). We also determined the effect of SENP1 on MMP expression in DU145, another prostate cancer cell line. Using two SENP1 small-interfering RNA oligos (Supplementary Figure S2) , we observed the similar results in DU145 (Figure 4b) As SENP1 regulates HIF1a activity through de-SUMOylation, we proposed that HIF1a mediates the SENP1 regulation of MMP expression. To address this issue, MMP2 promoter-driven luciferase was transfected into control or HIF1a-silenced U937 cells (Supplementary Figure S5) . Silencing HIF1a significantly downregulated the SENP1-induced MMP2 transcription (Figure 4e ), suggesting that HIF1a is essential for the SENP1 regulation of MMP2 expression. As mutation of SUMOylation sites could increase HIF1a activation, we expected that the mutant of SUMOylation sites of HIF1a would be more active than HIF1a wild type in induction of MMP expression. Indeed, the transactivation of MMP2 promoter in the mutant of SUMOylation sites of HIF1a (HIF1aSM)-transfected PC3 cells was significantly more than that in HIF1a-transfected cells (Figure 4f and Supplementary Figure S6 ). The expression of HIF1aSM in PC3 cells also showed more induction of MMP2 and MMP9 expression than that of HIF1a wild type (Figure 4g ). We further determined whether SENP1 was essential in the control of HIF1a-SUMOylation status by transfection of HA-SUMO1 into si-NS or si-SENP1-PC3 cells. As shown in Figure 4h , there were SUMOylated HIF1a proteins accumulated in si-SENP1-PC3 cells, not in si-NS-PC3 cells, after treatment with hypoxia plus MG132 (the top panel of Figure 4h ). These data indicate that SENP1 can de-SUMOylate HIF1a and regulate MMP2 and MMP9 expression in PC3 cells. (Hyclone), supplemented with 10% fetal bovine serum, 50 units per ml penicillin and 50 mg ml À 1 streptomycin. Si-NS and siSENP1-PC3 cells were generated by infection of retrovirus-based SENP1si-1 virus particles produced from pRS-Puro-SENP1 siRNA as described previously. ) were plated in serum-free medium into the upper chamber and allowed to migrate toward 10% FBS as a chemoattractant in the lower chamber for 22 h. Cells in the upper chamber were carefully removed using cotton buds, and cells at the bottom of the membrane were fixed and stained with nuclear fast red. The data are presented as means±s.e.m. of three independent experiments. (d) Male BALB/c nude mice (5 weeks old) were anesthetized with isoflurane gas and si-NS-PC3, si-SENP1-PC3 cells (5 Â 10 6 per mouse) were injected into the left ventricle. At 7 weeks after injection, mice were anesthetized and digital radiographs were taken by the Faxitron MX-20 machine with an X-ray current of 50 mA and a voltage of 33 kV (Faxitron X-ray). X-ray images of metastatic bone lesions (red arrow) of si-NS-or si-SENP1-PC3 cells after intracardiac injection (top panel). The hind limbs were fixed in 4% paraformaldehyde for 24 h, decalcified in 10% EDTA (pH 7.2) for 30 days and embedded in paraffin. The lesions were confirmed by staining sections with hematoxylin and eosin (bottom panel). In summary, this study reveals that SENP1 functions to promote prostate tumor growth and metastasis. We have identified the following evidences to support this conclusion. First, the analytical results of over 150 prostate cancer samples point out that there is overexpression of SENP1 in prostate cancer, and that the expression level of SENP1 significantly correlates to tumor aggressiveness and the risk of recurrence in prostate cancer patients after prostatectomy. Second, the change of SENP1 expression in prostate cancer cells can affect its ability to mediate tumor growth. Third, SENP1 directly contributes to the metastasis of prostate cancer cells to the bone and can also regulate the key bone remodeling proteins, MMP2 and MMP9, through the HIF1a SENP1 regulates prostate cancer progression Q Wang et al signaling pathway. These findings demonstrate a crucial role of SENP1 in the progression of prostate cancer and suggest that SENP1 may be a prognostic marker and therapeutic target for bone metastasis in prostate cancer patients.
